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ORIGINAL ARTICLE
Vaginal lactoferrin in prevention of preterm birth in women with
bacterial vaginosis
Marilena Miranda, Gabriele Saccone , Alessandra Ammendola, Emilia Salzano, Marisa Iannicelli,
Rossella De Rosa, Giovanni Nazzaro and Mariavittoria Locci
Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples “Federico II”,
Naples, Italy
ABSTRACT
Objective: To evaluate use of vaginal lactoferrin in prevention of preterm birth (PTB) in women
with first trimester bacterial vaginosis and prior spontaneous PTB.
Methods: This is a retrospective cohort study of all consecutive singleton gestations with prior
PTB, and first trimester diagnosis of bacterial vaginosis. Women who were found to have bacter-
ial vaginosis were recommended lactoferrin 300mg vaginal tablets daily for 21 days. The primary
outcome was the incidence of PTB at less than 37weeks of gestations. Outcomes were com-
pared in women who received daily lactoferrin with those who did not
Results: During the study period, 847 pregnant women with prior spontaneous PTB were
screened for bacterial vaginosis. Of them, 193 were found to have bacterial vaginosis in the first
trimester, with an overall incidence of 22.8%. Out of the 193 women, 125 met the inclusion cri-
teria for the study and were analyzed. Sixty of the included women received vaginal lactoferrin,
while 65 did not. Women who received supplementation with lactoferrin had a significantly
lower rate of PTB< 37weeks (25.0 versus 44.6%; p¼ .02), lower mean gestational age at delivery
(37.7 ± 3.2 versus 35.9 ±4.1weeks; p¼ .01), and lower rate of admission for threatened PTL (45.0
versus 70.8%; p¼ .04). No between-group differences were noticed in the other outcomes,
including chorioamnionitis, PPROM< 34weeks, and neonatal outcomes. No cases of late miscar-
riage were reported in our cohort. No cases of adverse events were reported.
Conclusion: Based on this small single-center retrospective study, supplementation with vaginal
lactoferrin in women with first trimester bacterial vaginosis may be an option to reduce the risk
of preterm delivery.
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Introduction
Prematurity is a leading cause of maternal and neo-
natal mortality and morbidity, complicating up to 10%
of all pregnancies [1]. Mortality and morbidities,
including respiratory distress syndrome (RDS), intra-
ventricular hemorrhage (IVH), necrotizing enterocolitis
(NEC) and sepsis, are inversely associated with gesta-
tional age at birth [1,2].
Different strategies have been adopted for preven-
tion of preterm birth (PTB), including cervical pessary,
cerclage, and progesterone [3–15]. Observational evi-
dence suggests that vaginal infection is implicated in
the genesis of spontaneous preterm labor (PTL), and
preterm premature rupture of membranes (PPROM)
[16–18]. Bacterial vaginosis in particular is associated
with about two to four-fold increased risk of PTB [17].
Therefore, some authors suggest universal screening
and treatment for bacterial vaginosis in pregnancy.
However, evidence from meta-analyses and random-
ized trials showed that screening and treatment of
bacterial vaginosis in low-risk pregnancies do not
reduce the risk of PTB [19–21]. Contrariwise, the effect
in women at high risk of preterm delivery for history
of prior spontaneous PTB is still a subject of debate
[22], although use of antibiotics are not currently rec-
ommended. In these patients, a treatment based on
vaginal lactoferrin may offered as an alternative and
safe approach [23–25] however, evidence of efficacy of
lactoferrin in prevention of PTB are still lacking.
Objective
Thus, the aim of this study was to evaluate use of
vaginal lactoferrin in prevention of PTB in women
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with first trimester bacterial vaginosis and prior spon-
taneous PTB.
Materials and methods
Study design
This was a retrospective study using data collected
prospectively from clinical records of all consecutive
pregnant women with prior PTB who were referred to
the University of Naples “Federico II” from January
2016 to January 2019. Only women with singleton
gestations and history of prior spontaneous PTB at 16
0/7 36 6/7week of gestation were included in the
database. Data were collected with the patient con-
sent and were anonymized before analysis.
Women with prior PTB were screening for bacterial
vaginosis using vaginal swab in the first prenatal vis-
it< 13weeks of gestations. Women who were found
to have bacterial vaginosis, based on established diag-
nostic criteria [26], were included in the study. Women
without bacterial vaginosis at the first prenatal visit,
and those with first prenatal visit > 13weeks of gesta-
tions were excluded from the study.
Women who were found to have bacterial vaginosis
were recommended lactoferrin 300mg vaginal tablets
Medical device (MD) daily for 21 days, starting from
January 2018. Before January 2018, women were not
recommended any treatment.
Primary and secondary outcomes
The primary outcome was the incidence of PTB at less
than 37weeks of gestations. The secondary outcomes
were spontaneous late miscarriage, defined as delivery
between 16 and 21weeks; hospitalization for threat-
ened preterm labor; chorioamnionitis; preterm prema-
ture rupture of membranes (PPROM) at less than
34weeks of gestations; and neonatal outcomes,
including birth weight and admission to neonatal
intensive care unit (NICU).
Primary and secondary outcomes were compared in
women who received vaginal lactoferrin with those
who did not.
Statistical analysis
Statistical analysis was performed using Statistical
Package for Social Sciences (SPSS) v. 19.0 (IBM Inc,
Armonk, NY, USA). Data were shown as means ± stan-
dard deviation or as number (percentage). Univariate
comparisons of dichotomous data were performed
with the use of the chi-square test with continuity
correction. Comparisons between groups were per-
formed with the use of the T-test to test group means
by assuming equal within-group variances.
p Values< .05 was considered statistically
significant.
Results
During the study period, 847 pregnant women with
prior spontaneous PTB were screened for bacterial
vaginosis. Of them, 193 were found to have bacterial
vaginosis in the first trimester, with an overall inci-
dence of 22.8%. Out of the 193 women, 125 met the
inclusion criteria for the study and were analyzed. 60
of the included women received vaginal lactoferrin,
while 65 did not.
The two groups were similar in terms of maternal
demographics. The mean maternal age was about
28 years, and the mean BMI was about 21. Most of the
included women were Caucasian, 53 and 57 in the
lactoferrin and in the control group, respectively.
Overall 12% (15/125) of the women were smokers.
Sixty-one women received progesterone, four received
Arabin pessary, and three patients received cervical
cerclage (Table 1).
Women who received supplementation with lactofer-
rin had a significantly lower rate of PTB< 37weeks (25.0
versus 44.6%; p¼ .02), lower mean gestational age at
delivery (37.7±3.2 versus 35.9 ±4.1weeks; p¼ .01), and
lower rate of admission for threatened PTL (45.0 versus
70.8%; p¼ .04). No between-group differences were
noticed in the other outcomes, including chorioamnioni-
tis, PPROM< 34weeks, and neonatal outcomes. No
cases of late miscarriage were reported in our cohort.
No cases of adverse events were reported (Table 2).
Discussion
Main findings
This study aimed to evaluate the efficacy of lactoferrin
in reducing the incidence of PTB in singleton
Table 1. Maternal demographic characteristics.
Lactoferrin group
N¼ 60
Control group
N¼ 65 p-Value
Age (years) 27.6 ± 6.0 28.7 ± 6.3 .32
BMI 21.7 ± 1.8 21.4 ± 1.8 .78
Race
White 53 (88.3%) 57 (87.7%) .56
Smoking 7 (11.7%) 8 (12.3%) .57
Progesterone 52 (86.7%) 59 (90.8%) .51
Cervical pessary 1 (1.7%) 3 (4.6%) .34
Cervical cerclage 1 (1.7%) 2 (3.1%) .53
Data are presented as number (percentage) or as mean ± stan-
dard deviation.
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gestations with prior PTB, and with first trimester bac-
terial vaginosis. In our study the incidence of bacterial
vaginosis in a cohort of women with prior spontan-
eous PTB was 22.8%. Women who were recommended
lactoferrin 300mg vaginal tablets daily for 21 days had
a significantly lower rate of PTB at less than 37weeks
of gestation. Those women also had less chances to
be admitted for threated PTL. We also reported a non-
significantly lower incidence of admission to NICU in
the lactoferrin group.
The most important limitation of our study is the
retrospective, nonrandomized approach. A priori power
analysis could not be assessed due to its retrospective
nature. The number of women included were small
due to the restrictive inclusion criteria. Compliance
with therapy was not measured. No cost-effectiveness
analysis was assessed. The incidence of preterm deliv-
ery was higher that expected in our cohort, with an
incidence of 44.6% of PTB< 37weeks, and a 70.8%
rate of women admitted inpatient for threatened PLT.
Notable, the included women, ie women with prior
PTB and with bacterial vaginosis, are patients with
high baseline risk of PLT.
Implications
Bacterial vaginosis is characterized by a dysbiosis of
the vaginal microbiota where protective Lactobacillus
spp. are replaced by a mixed anaerobic microbiota,
including Gardnerella vaginalis and Mobiluncus spp.
morphotypes [27,28]. Symptoms of bacterial vaginosis
include vaginal discharge and fishy odor, but most of
the women are asymptomatic. One problem with bac-
terial vaginosis, is the inconsistencies in the diagnosis.
Initially, it was diagnosed with Amsel criteria, then
largely replaced by the Nugent criteria [26,27,29].
Recently, polymerase chain reaction (PCR) of bacter-
ium-specific 16S rDNA has been used to detect bac-
teria associated with bacterial vaginosis [28–30].
Bacterial vaginosis, especially when present in early
pregnancy, has been associated with an increased risk
of preterm delivery, early pregnancy loss, low birth
weight, increased neonatal morbidity, and higher rates
of postpartum endometritis. Despite the strength of
evidence linking infection with preterm labor and
delivery and perinatal complication, most of the
efforts to prevent these complications with antibiotics
have been not successful [19–21,31–33]. Romero and
other experts suggest that this may be explained by
the fact that PTB is a syndrome and the infection is
only one of its causes, and by the fact that the odds
ratio for PTB in women with bacterial vaginosis is
low [31–33].
Notably, antimicrobial agents are drugs that alter
the microbial ecosystems, including the vaginal micro-
biome. Antibiotic administration may alter the vaginal
flora and predispose to vaginal candidiasis and other
infections, and can affect intestinal, urinary tract, and
periodontal flora. These theories may also explain the
increased risk in preterm labor in women receiving
antibiotics compared to placebo in several randomized
trials [19–21]. For these reasons, other nonantibiotic
agents have been studies in order to reduce the risk
of PTB in women with bacterial vaginosis.
Gardnerella vaginalis proliferation is dependent on
iron, whereas lactobacilli require manganese [29].
Lactoferrin is an iron-binding protein that is elevated
in the vaginal discharge of patients with bacterial
vaginosis. This suggests that the increased lactoferrin
production may be a host response to limit prolifer-
ation of iron-requiring bacteria [29]. Moreover, in ani-
mal model, human lactoferrin showed a potential to
suppress uterine cervical ripening [25]. Therefore, sup-
plementation with oral or vaginal lactoferrin has been
proposed as an alternative approach for pregnant
women with bacterial vaginosis [23,24]. To the best of
our knowledge, this study may be the first clinical
observational cohort study showing efficacy of vaginal
lactoferrin in reducing the risk of PTB in women with
bacterial vaginosis.
Conclusions
In summary, based on this small single-center retro-
spective study, supplementation with lactoferrin in
women with first trimester bacterial vaginosis may be
a safe option to reduce the risk of preterm delivery.
Disclosure statement
No potential conflict of interest was reported by the authors.
Table 2. Primary and secondary outcomes.
Lactoferrin group
N¼ 60
Control group
N¼ 65 p-Value
PTB < 37 weeks 15 (25.0%) 29 (44.6%) .02
GA at delivery (weeks) 37.7 ± 3.2 35.9 ± 4.1 .01
Late miscarriage 0 0 –
Threatened PTL 27 (45.0%) 46 (70.8%) .04
Chorioamnionitis 2 (3.3%) 6 (9.2%) .27
PPROM < 34 weeks 1 (1.7%) 2 (3.1%) .53
Birth weight (grams) 2,808 ± 719 2,625 ± 831 .19
Admission to NICU 5 (8.3%) 14 (21.5%) .05
Data are presented as number (percentage) or as mean ± stan-
dard deviation.
PTB: preterm birth; GA: gestational age; PTL preterm labor; NICU: neo-
natal intensive care unitBoldface data, statistically significant.
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